CARLOS FONTE: Open Payments
NPI 1215979604 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$466 in 22 payments from 8 companies in 2025. Trend: 2023 $863 · 2024 $554 · 2025 $466
Food & beverage: $466
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $117 |
| Novartis Pharmaceuticals Corporation | 5 | $109 |
| E.R. Squibb & Sons, L.L.C. | 3 | $71 |
| Alnylam Pharmaceuticals Inc. | 2 | $69 |
| Abbott Laboratories | 2 | $46 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
| Koya Medical, Inc. | 1 | $15 |
Products named: REPATHA, LEQVIO, AMVUTTRA, ELIQUIS, JOT DX, CAMZYOS, Venclose Maven Catheter, JARDIANCE.
Industry payments across NV — which companies pay providers there.
